Hematological toxicity of 89SrCl2 in patients with multiple bone metastases

Abstract

Objective To observe the hematological toxicity of 89SrCl2 in patients with multiple bone metastases of malignant tumors, and analyze the related-risk factors. Methods A total of 89 patients (63 males, 26 females; age: (62.3±5.2) years) with multiple bone metastases and treated with 89SrCl2 were enrolled. Hematological data at 2 and 4 weeks after treatment with 89SrCl2 were analyzed. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 was used to evaluate the hematological toxicity, and the influencing risk factors were analyzed. Logistic regression analysis was used to analyze the data. Results The incidences of grade Ⅰ-Ⅱ anemia, leukopenia and thrombocytopenia at 2 and 4 weeks after treatment were 15.7%(14/89), 18.0%(16/89), 11.2%(10/89) and 18.0%(16/89), 24.7%(22/89), 18.0%(16/89), respectively. The incidences of grade Ⅲ-Ⅳ anemia, leukopenia and thrombocytopenia were 2.2%(2/89), 0, 0 and 2.2%(2/89), 2.2%(2/89), 3.4%%(3/89), respectively. Logistics multivariate analysis showed that the number of bone metastases and the Hb level before treatment were independent effect factors for hematological toxicity of 89SrCl2, with odds ratio (OR) values of 2.200(95% CI: 1.269-3.841) and 0.961(95% CI: 0.932-0.991), respectively. Conclusions Serious hematological toxicity after 89SrCl2 treatment is rare. The number of bone metastases and the Hb level before treatment are independent effect factors for hematological toxicity. Key words: Neoplasm metastasis; Skeleton; Radiotherapy; Strontium radioisotopes; Drug-related side effects and adverse reactions; Blood